Guizhou Xinbang Pharmaceutical's subsidiary is embroiled in a bribery scandal; what is the impact?

① Company personnel stated that this matter currently has no impact on the company's operation, and the subsidiary mainly engages in in-hospital pharmaceutical wholesale. Even if penalized later, it will not involve qualification issues. ② Industry experts believe that the short-term impact is significant, while the long-term impact is minimal. In the short term, the principal company may be listed as untrustworthy due to the crime of unit bribery, which would exclude it from the bidding procurement of local hospitals in Guizhou for a period. However, in the long term, since it is not a quality issue, there are opportunities for repair.

cls.cnMar 4 09:08 ET

Former TJ DaRenTang Chairman Zhang Mingrui has taken over as General Manager of Hainan Huluwa Pharmaceutical Group, responsible for the company's overall Operation work | Quick read announcement

① Former TJ DaRenTang Chairman Zhang Mingrui has been appointed General Manager of Hainan Huluwa Pharmaceutical Group. Company sources indicate, "Chairman Liu Jingping will primarily focus on the work related to the Board of Directors in the future, while General Manager Zhang Mingrui will be responsible for the company's overall Operation." ② Company sources also noted that this year marks the year of Hainan's customs closure, and the company is facing significant opportunities for strategic development. The company's invitation for Mr. Zhang is also strategical.

cls.cnMar 4 06:15 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

The amount involved exceeds 0.5 billion yuan and the equity transfer dispute of China Meheco Group is still ongoing | Quick read of the announcement.

① China Meheco Group has appealed to the court regarding the acquisition of the remaining 30% equity in Jinlun Pharmaceutical (now named Hebei Tongyong) held by Wang Yibing; ② The amount involved in this lawsuit reaches 0.51 billion yuan.

cls.cnFeb 28 10:46 ET

Tasly Pharmaceutical Group's net income has declined by 10%, and the progress of equity transfer may accelerate | Interpretations

① Tasly Pharmaceutical Group achieved a total operating revenue of 8.498 billion yuan in 2024, a decrease of 2.03% year-on-year; Net income attributable to the parent company was 0.956 billion yuan, a decrease of 10.78% year-on-year. ② The current Shareholders are actively advancing the transfer of shares and have begun to sort out and confirm the actual used Assets and subsidiary Assets of the company.

cls.cnFeb 24 10:10 ET

Another "miracle drug for myopia" application has been accepted, will Shenyang Xingqi Pharmaceutical's "star product" be impacted? | Quick announcement review

①The application for marketing authorization of HR19034 eye drops under Jiangsu Hengrui Pharmaceuticals has been accepted by the National Medical Products Administration, challenging the exclusive position of Shenyang Xingqi Pharmaceutical. ② The atropine sulfate eye drops suitable for myopia in adolescents under several pharmaceutical companies have all entered phase 3 clinical trials.

cls.cnFeb 17 11:21 ET